Angelo Oliva MD

Results from SYDNEY4 IPD analysis just presented by @vlgmrc at @escardio and sim published.

Ticagrelor mono vs DAPT in >20.000 pts from 6 RCTs, pre-specified ACS vs CCS.

Is this the conclusive evidence?
Read our editorial in @TheLancet @GGStefanini thelancet.com/journals/lance…

Ticagrelor Monotherapy reduced bleeding without increasing ischemic events in 7,529 ACS patients from TWILIGHT and TICO trials pooled analysis
Our study led by @Drroxmehran and presented by
@ubcardio at #TCT2023 simultaneously published in @CircAHA ahajournals.org/doi/10.1161/CI…

So proud to see our network metanalysis on antithrombotic strategies in patients with CAD finally published in #EHJPharmacotherapy. +40 trials and 250k patients included. This paper informed the upcoming EAPCI/ACVC/EAPC consensus document. Stay tuned!
academic.oup.com/ehjcvp/advance…

Take a look to our review about AI application for CV risk prediction just published on #ECRjournal 👉 ecrjournal.com/articles/artif… @radcliffeCARDIO @ChiaritoMauro @GGStefanini @gcondorelli #ArtificialIntelligence #Cardiology

How to improve antithrombotic therapy net benefit and the promising role of novel FXIa inhibitors. Terrific session held by @Drroxmehran and @VijayKunadian at @CVCTForum in Washington DC. #cvct2022 #thrombosis #trialist